LG 268
Latest Information Update: 07 Feb 2001
At a glance
- Originator Ligand Pharmaceuticals; Tularik; University of Texas Southwestern Medical Center
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol absorption inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for Hypercholesterolaemia in USA (Unknown route)
- 01 Nov 2000 New profile
- 01 Nov 2000 Preclinical development for Hypercholesterolaemia in USA (Unknown route)